NASDAQ:RARX Ra Pharmaceuticals (RARX) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free RARX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$47.99▼$47.9950-Day Range$47.99▼$48.0052-Week Range$19.64▼$48.02Volume30,200 shsAverage Volume1.16 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ra Pharmaceuticals alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Ra Pharmaceuticals Stock (NASDAQ:RARX)Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. RARX Stock News HeadlinesJanuary 23, 2024 | seekingalpha.comRA: Discount Continues To Leave Some OpportunitySeptember 8, 2023 | barrons.comImperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist InvestorsApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.May 29, 2023 | thestreet.comAnthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public OfferingJanuary 10, 2023 | msn.comUPDATE 1-AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealNovember 15, 2022 | 247wallst.comRA Capital Closes Position in Astria Therapeutics (ATXS)August 20, 2022 | investing.comRARX_old Historical DataJune 12, 2022 | msn.comPhilly-area pharma firm raises $118M for high blood pressure drugApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.June 8, 2022 | msn.comPhilly-area pharma firm raises $118M for high blood pressure drug for those who need extra helpMay 16, 2022 | finance.yahoo.comRa Medical Systems Reports First Quarter 2022 Financial ResultsSee More Headlines Receive RARX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RARX CUSIPN/A CIK1481512 Webwww.rapharma.com Phone617-401-4060FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.61% Return on Assets-41.60% Debt Debt-to-Equity Ratio0.01 Current Ratio14.78 Quick Ratio14.79 Sales & Book Value Annual Sales$3 million Price / Sales757.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book8.63Miscellaneous Outstanding Shares47,329,000Free FloatN/AMarket Cap$2.27 billion OptionableOptionable Beta1.05 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Douglas A. Treco (Age 61)Co-Founder, Pres, CEO & Director Mr. David C. Lubner (Age 55)Exec. VP & CFO Dr. Ramin Farzaneh-Far (Age 42)Chief Medical Officer Mr. Alonso RicardoChief Technology & Innovation Officer and Head of ResearchDr. Simon Read (Age 48)Chief Scientific Officer Key CompetitorsAimmune TherapeuticsNASDAQ:AIMTArvinasNASDAQ:ARVNTG TherapeuticsNASDAQ:TGTXDyne TherapeuticsNASDAQ:DYNVera TherapeuticsNASDAQ:VERAView All Competitors RARX Stock Analysis - Frequently Asked Questions How were Ra Pharmaceuticals' earnings last quarter? Ra Pharmaceuticals Inc (NASDAQ:RARX) announced its earnings results on Thursday, February, 27th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.16. What other stocks do shareholders of Ra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Novavax (NVAX), Viking Therapeutics (VKTX), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN), Galmed Pharmaceuticals (GLMD), Immunomedics (IMMU) and Rigel Pharmaceuticals (RIGL). When did Ra Pharmaceuticals IPO? Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering (IPO) on Wednesday, October 26th 2016. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager. This page (NASDAQ:RARX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ra Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.